Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Clinical Trials
21
0 active
Approvals
1
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Completed
19
90.5%
Withdrawn
2
9.5%
- Ligand Pharmaceuticals reported second-quarter 2026 royalty revenue of $48 million, a 32% year-over-year increase driven by Filspari, Ohtuvayre, and Zelsuvmi. - The company completed its $700 million zero-coupon convertible debt financing and closed the XOMA Royalty acquisition, adding more than 120 assets to its portfolio. - Full-year 2026 adjusted EPS guidance was raised at the low end to $9.00 (range: $9.00–$9.50), with royalty revenue guidance reaffirmed at $225–$250 million. - Key pipeline catalysts include Filspari's FSGS approval, Capvaxive's pediatric label expansion, and upcoming pivotal readouts across seven programs over the next 18 months.
- Director John W. Kozarich sold 2,501 shares of Ligand Pharmaceuticals in open-market transactions between May 1 and May 13, 2026, according to an SEC Form 4 filing. - The transaction, valued at approximately $563,000, was structured via option exercise and immediate disposal, representing a liquidity event rather than a discretionary sale. - Kozarich retains 41,786 common shares directly, with post-transaction holdings valued at approximately $9.24 million based on the May 13, 2026 market close. - Ligand's partnership-driven royalty model generates revenue from a diversified portfolio including Kyprolis, Evomela, Veklury, and Captisol-enabled formulations, offering investors exposure without clinical-stage binary risk.
- Intravacc and Primrose Bio have renewed their strategic partnership to enhance conjugate vaccine development and manufacturing capabilities for third-party clients. - The collaboration combines Intravacc's expertise in vaccine conjugation and GMP production with Primrose Bio's PeliCRM197® carrier protein technology. - The partnership creates a seamless full-service solution spanning from early-stage development through clinical manufacturing for vaccine developers. - PeliCRM197® represents the only CRM197 carrier protein used in commercial vaccines that is available for purchase, offered in research and GMP grades.
- Ligand Pharmaceuticals announced the acquisition of fellow biotech royalty aggregator XOMA Royalty for $739 million in cash, paying $39 per share with a 3% premium. - The deal adds more than 120 treatments to Ligand's portfolio, including seven marketed products such as Roche's Vabysmo, expanding the total portfolio to over 200 drugs. - Ligand raised its 2026 revenue outlook to $270-310 million and adjusted profit forecast to $8.50-9.50 per share, with the acquisition expected to be immediately accretive. - The company expects to earn $37.5 million annually at peak from royalties on eye drug Vabysmo and retains capacity to invest $150-250 million annually in additional royalty assets.
- Arecor Therapeutics is targeting a Phase II clinical trial for its ultra-concentrated insulin AT278 in the second half of 2026, following positive FDA feedback on its innovative study design. - The company is developing AT278 as a "best-in-class ultra-concentrated (500 U/mL) and ultra-rapid-acting insulin" through a 50:50 co-development partnership with Sequel Med Tech. - Arecor is also advancing an oral GLP-1 platform aimed at improving bioavailability beyond the current less than 1% achieved by existing treatments like Rybelsus. - The company reported cash reserves of £6.1 million at year-end 2025, extending its operational runway into the first half of 2027.
- Pelthos Therapeutics acquired U.S. commercialization rights to Xepi (ozenoxacin) cream, the first new impetigo treatment approved in over 10 years, addressing critical antibiotic resistance issues. - The FDA-approved topical antimicrobial targets impetigo caused by Staphylococcus aureus and Streptococcus pyogenes, affecting approximately 3 million Americans annually, primarily children ages 2-5. - The company secured $18 million in convertible notes financing to support Xepi's re-launch in late 2026 and accelerate commercialization of its molluscum contagiosum treatment ZELSUVMI. - Xepi represents a significant therapeutic advancement as one of few treatments effective against both methicillin-resistant and mupirocin-resistant Staphylococcus aureus infections.
- Ligand Pharmaceuticals and SQ Innovation Inc. received FDA approval for Lasix ONYU, a drug-device product enabling adults with chronic heart failure to manage edema at home. - The FDA clearance has fueled market optimism, with Ligand's shares surging 46% over the past three months and delivering nearly 73% total shareholder return over one year. - Analysts maintain seven buy ratings for Ligand, reflecting strong confidence in the company's biotechnology strategy despite some profitability challenges. - The company's fair value is estimated at $183.12, suggesting a 2.9% undervaluation compared to the last closing price of $177.73.
- A comprehensive 2025 clinical trials review reveals the current global research landscape for alopecia universalis, analyzing trial distribution across regions, phases, and sponsor types. - Major pharmaceutical companies including Pfizer, Johnson & Johnson, Roche, and Aclaris Therapeutics are actively participating in alopecia universalis therapeutic development programs. - The report provides critical insights into trial enrollment trends over the past five years and identifies prominent drugs currently in development for this severe autoimmune hair loss condition. - Clinical trial data is compiled from over 80 different registries worldwide, offering stakeholders comprehensive market intelligence for strategic decision-making in dermatology therapeutics.
- Pelthos Therapeutics has commercially launched ZELSUVMI (berdazimer) topical gel 10.3%, the first FDA-approved prescription medication for molluscum contagiosum that can be applied at home by patients or caregivers. - The nitric oxide-releasing gel demonstrated significant efficacy in the largest Phase 3 molluscum study to date, achieving complete lesion clearance in 33% of patients versus 19.7% with placebo at 12 weeks. - Molluscum contagiosum affects an estimated 16.7 million Americans with up to 6 million new cases annually, yet up to 73% of pediatric cases go untreated due to limited therapeutic options and inconvenient procedural treatments.
- Ligand Pharmaceuticals' subsidiary Pelthos Therapeutics will merge with Channel Therapeutics in a $50 million transaction, creating a publicly traded company focused on commercializing Zelsuvmi for molluscum contagiosum infections. - Zelsuvmi, approved by the FDA in 2024, is the first and only prescription therapy for molluscum that can be administered at home by patients, parents, or caregivers, addressing a condition affecting an estimated 16.7 million Americans. - The combined company will retain Channel's NaV 1.7 development programs for various pain indications while Ligand will maintain a 13% royalty on worldwide Zelsuvmi sales, with the transaction expected to close in summer 2025.
